Search for…

• Realizing the benefits of gene silencing – Novel HDAC6 inhibitor for the treatment of inflammatory diseases

  B73271 | B77007

  Realizing the benefits of gene silencing – Novel HDAC6 inhibitor for the treatment of inflammatory diseases

  • Oral HDAC6 inhibitor with superior specificity
  • Anti-inflammatory effect in in vivo arthritis model
  • Alternative to first line anti-inflammatory drugs
• Cutting cost and time – HCV immunoassay predicts clinical response rate to antiviral treatment

  B76124

  Cutting cost and time – HCV immunoassay predicts clinical response rate to antiviral treatment

  • Antiviral drugs for HCV are effective but expensive
  • Immunoassay can predict response to antiviral drugs
  • Significant reduction of long-term treatment cost
• Success Prediction of an Allergen- specific Immunotherapy

  B76137

  Success Prediction of an Allergen- specific Immunotherapy

  • Innovative prediction method for the therapeutic success of an allergen-specific immunotherapy (AIT) at an early stage
  • straightforward and easy determination of the relevant parameters from nasal sample material
  • patient-friendly and economic
• NF-κB-activated dendritic cells

  B71259

  NF-κB-activated dendritic cells

  • that has very little adverse effects and overcomes the limitations of DC based immunotherapy approaches
  • DCs activation is mediated by via mRNA transfection
  • Activated DCs lead to strong expansion of memory T cells and are much more stable than other DC vaccination products
• Improving Stability and Secretion of ­Antibodies

  B73076

  Improving Stability and Secretion of ­Antibodies

  • Improvement of the biophysical properties of antibodies and enhancement of antibody secretion by imitating the stabilizing structural elements of shark antibodies
  • CL domain is modified by a conservative exchange of amino acids at two positions
  • Compared to the wild type CL, the melting point of the modified CL domain is almost 10°C higher and its stability against urea-induced denaturation is also markedly increased
• Small molecule inhibitors of CD40-TRAF6 ­interactions

  B72031

  Small molecule inhibitors of CD40-TRAF6 ­interactions

  • New selective inhibitors for treatment of chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis.
  • Inhibitors selectively block CD40-TRAF6 interactions
  • The selective blockage of the CD40-TRAF6 interactions strongly reduces inflammation, whereas unwanted immune-suppressive side effects are reduced

6 of 95 Tech Offers